Humira's Inevitable Decline: What's Waiting In The Wings?

 
• By Lucie Ellis-Taitt

There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.

Business decline
World's best-selling drug Humira faces big losses as biosimilar versions wait in line • Source: Shutterstock

More from Drug Pricing

More from Scrip